GlassScriptPhysician profile
Sarah Lynn Helms
NPI 1083964290
$7,165.34
in general payments reported to CMS, 2019-2025
37 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.63 · 2022: $107 · 2023: $2,395 · 2024: $1,986 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,028 · Entertainment: $14.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,028.30 |
| Entertainment | $14.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.96 | 2023-2025 | |
| Gilead Sciences, INC. | $1,028.40 | 2022-2025 | Biktarvy |
| Viiv Healthcare Company | $835.77 | 2023-2025 | Cabenuva, Dovato, Apretude |
| Astrazeneca Pharmaceuticals LP | $649.68 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $479.89 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $425.22 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $274.13 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $240.73 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Glaxosmithkline, LLC. | $232.86 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $232.21 | 2023-2025 | |
| Lilly USA, LLC | $194.51 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $188.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $172.04 | 2025 | Repatha |
| Astellas Pharma US INC | $148.70 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.45 | 2023-2025 | Xifaxan, Trulance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $113.42 | 2023 | Symtuza |
| Idorsia Pharmaceuticals US INC | $110.56 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $102.80 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.25 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $67.03 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.02 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $48.28 | 2023 | Gemtesa |
| Abbott Laboratories | $45.14 | 2023 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $41.89 | 2023 | Symtuza |
| Vanda Pharmaceuticals INC. | $30.44 | 2023 | Hetlioz, Fanapt |
| Tris Pharma INC | $23.47 | 2025 | Dyanavel Xr |
| Daiichi Sankyo INC. | $23.36 | 2023 | Injectafer |
| Alvogen INC | $22.56 | 2025 | Teriparatide |
| Lundbeck LLC | $20.58 | 2025 | Rexulti |
| Boston Scientific Corporation | $19.28 | 2025 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $19.11 | 2023 | Gattex |
| Edwards Lifesciences Corporation | $18.99 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shield Therapeutics INC | $17.50 | 2025 | |
| Coopersurgical, INC. | $15.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.12 | 2025 | Zoryve |
| Optos, INC. | $14.09 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tolmar, INC. | $13.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Helms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.